Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is a clinical-stage biopharmaceutical company with a diverse portfolio of multifunctional biotherapeutics, including its lead candidate, zanidatamab, which has shown promising results in clinical trials for various cancers. The company's strategic partnerships and potential for multiple revenue streams, through milestones, royalties, and product sales, make it an attractive investment opportunity. However, the inherent risks in the biopharmaceutical industry, such as clinical setbacks or competition from other drugs, must be considered. With the recent FDA approval of zanidatamab and the potential for future successes, the company's positive outlook is driven by its potential for strong financial performance and a robust pipeline.

Bears say

Zymeworks is a clinical-stage biopharmaceutical company that is heavily reliant on the success of its lead candidate, zanidatamab, for revenue. While the recent FDA approval and milestone payment from Jazz Pharmaceuticals are positive developments, the company's product pipeline and financials are heavily dependent on this single asset. Additionally, competition, regulatory and financial risks, as well as uncertainties around potential strategic transactions, could have a significant impact on the company's future performance.

Zymeworks Inc (ZYME) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 10 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.